IFNA2 and neoplasm: Replacing wild-type IFN-α with an engineered, attenuated version (att) with the capability of inducing proinflammatory markers decreased the toxicity of CD38-(att)IFN-α for animals 100-fold, without substantial loss of anti-tumor activity.